罗格列酮
药品
体内
转录组
药理学
抗病毒药物
药物重新定位
STAT1
生物
体外
干扰素
药物发现
A549电池
病毒学
医学
免疫学
生物信息学
受体
基因表达
基因
生物化学
生物技术
作者
Xiaolong Wang,Song He,Zhe Zhou,Xiaochen Bo,Dongmei Qi,Xianjun Fu,Zhenguo Wang,Jing Yang,Shengqi Wang
标识
DOI:10.1016/j.antiviral.2020.104789
摘要
Human adenoviruses (HAdVs) often cause mild respiratory infections. These infections, however, can potentially become fatal in immunosuppressive patients. Unfortunately, there has been no specific anti-HAdV drug approved for treatment of HAdV infections. In this study, a time-course transcriptome of HAdV-infected human lung epithelial cells (A549 cells) was performed and compared with perturbation datasets of 890 drug-treated A549 cells from the library of integrated network-based cellular signatures (LINCS) database to predict previously unknown therapeutic drug-HAdV relationships using a characteristic direction (CD) algorithm. We performed experiments to validate a prediction for the anti-diabetic drug rosiglitazone as a candidate drug for treatment of anti-HAdV both in vivo and in vitro. The Type I interferon (IFNs) signaling pathway was negatively regulated during the course of HAdV infection and rosiglitazone increased STAT1 phosphorylation for antiviral IFN response induction. Taken together, this study confirmed the prospect for re-exploitation of this FDA-approved drug as a potential therapeutic for HAdV infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI